1. Home
  2. CUE vs BRID Comparison

CUE vs BRID Comparison

Compare CUE & BRID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • BRID
  • Stock Information
  • Founded
  • CUE 2014
  • BRID 1932
  • Country
  • CUE United States
  • BRID United States
  • Employees
  • CUE N/A
  • BRID N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • BRID Specialty Foods
  • Sector
  • CUE Health Care
  • BRID Consumer Staples
  • Exchange
  • CUE Nasdaq
  • BRID Nasdaq
  • Market Cap
  • CUE 94.4M
  • BRID 93.2M
  • IPO Year
  • CUE 2018
  • BRID N/A
  • Fundamental
  • Price
  • CUE $1.32
  • BRID $10.09
  • Analyst Decision
  • CUE Strong Buy
  • BRID
  • Analyst Count
  • CUE 5
  • BRID 0
  • Target Price
  • CUE $5.00
  • BRID N/A
  • AVG Volume (30 Days)
  • CUE 195.8K
  • BRID 1.6K
  • Earning Date
  • CUE 03-10-2025
  • BRID 03-07-2025
  • Dividend Yield
  • CUE N/A
  • BRID N/A
  • EPS Growth
  • CUE N/A
  • BRID N/A
  • EPS
  • CUE N/A
  • BRID N/A
  • Revenue
  • CUE $9,532,000.00
  • BRID $223,645,000.00
  • Revenue This Year
  • CUE $73.11
  • BRID N/A
  • Revenue Next Year
  • CUE $11.02
  • BRID N/A
  • P/E Ratio
  • CUE N/A
  • BRID N/A
  • Revenue Growth
  • CUE 149.53
  • BRID N/A
  • 52 Week Low
  • CUE $0.45
  • BRID $7.77
  • 52 Week High
  • CUE $2.37
  • BRID $14.69
  • Technical
  • Relative Strength Index (RSI)
  • CUE 48.32
  • BRID 43.86
  • Support Level
  • CUE $1.22
  • BRID $10.00
  • Resistance Level
  • CUE $1.54
  • BRID $10.31
  • Average True Range (ATR)
  • CUE 0.11
  • BRID 0.13
  • MACD
  • CUE -0.01
  • BRID -0.03
  • Stochastic Oscillator
  • CUE 35.29
  • BRID 27.57

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are processing and distribution of frozen products, and processing and distribution of snack food products. It includes products such as biscuits, bread dough items, roll dough items, dry sausage products, and beef jerky. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. It derives a majority of its revenue from snack food products.

Share on Social Networks: